855 Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses

855 Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses

Bibliographic Details
Main Authors:	Shannon Wongvibulsin, Jarushka Naidoo, Yevgeniy Semenov, Shawn Kwatra, Thomas Le, Subuhi Kaul, Laura Cappelli
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
by: Thomas K. Le, et al.
Published: (2022-04-01)

1251 Seasonal and geographic patterns in cutaneous immune-related adverse events after treatment with immune checkpoint inhibitors: a multicenter analysis
by: Kerry Reynolds, et al.
Published: (2023-11-01)

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
by: Christopher Cluxton, et al.
Published: (2023-07-01)

Embracing machine learning and digital health technology for precision dermatology
by: Shannon Wongvibulsin, et al.
Published: (2020-07-01)

Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration
by: Wenxin Chen, BS, et al.
Published: (2022-12-01)

Immune-related adverse events and the balancing act of immunotherapy
by: Michael Conroy, et al.
Published: (2022-01-01)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
by: Aanika Balaji, et al.
Published: (2020-06-01)

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
by: Kendall F. Moseley, et al.
Published: (2018-10-01)

Food and drug administration approval process for dermatology drugs in the United States
by: Emily Boozalis, et al.
Published: (2018-08-01)

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
by: Jarushka Naidoo, et al.
Published: (2022-06-01)

Corticosteroid-resistant immune-related adverse events: a systematic review
by: Laura C Cappelli, et al.
Published: (2024-01-01)

Histological And Histochemical Studies Of Epidermal Reactive Dermatoses And Urticaria
by: Ito Minor
Published: (2001-01-01)

The Performance of Pindar, <i>Pythian</i> 8.55-70
by: Edwin D. Floyd
Published: (2002-12-01)

Ocular and periocular tumors in 855 Asian Indian geriatric patients
by: Swathi Kaliki, et al.
Published: (2021-01-01)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021-01-01)

Dermatoses em Africanos / Dermatoses in Africans
by: Ana Marcos- Pinto, et al.
Published: (2018-06-01)

P855: Traceback testing for ovarian cancer: Implementer and participant perspectives*
by: Nora Henrikson, et al.
Published: (2024-01-01)

Abstract 8.55 PRECLINICAL AND CLINICAL APPROACHES IN PERIPHERAL NERVE SURGERY
by: Tim Kornfeld, et al.
Published: (2018-06-01)

Transcriptional Differences between Canine Cutaneous Epitheliotropic Lymphoma and Immune-Mediated Dermatoses
by: Nadja Gerber, et al.
Published: (2021-01-01)

Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
by: Chieh-Hsun Chen, et al.
Published: (2022-04-01)

Racial disparities in the management of acne: evidence from the National Ambulatory Medical Care Survey, 2005–2014
by: Andrew T. Rogers, et al.
Published: (2018-04-01)

Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis
by: Nina B. Curkovic, et al.
Published: (2024-01-01)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
by: Taiseer Al-Rajabi, et al.
Published: (2023-09-01)

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
by: Laura C Cappelli, et al.
Published: (2024-04-01)

P855: SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA
by: U. Keller, et al.
Published: (2022-06-01)

15.082J / 6.855J Network Optimization, Spring 2003
by: Orlin, James
Published: (2003)

Incidence and care of environmental dermatoses in the high-altitude region of Ladakh, India
by: G K Singh, et al.
Published: (2013-01-01)

Vulval dermatoses.
by: Howard, A, et al.
Published: (2003)

Paraneoplastic Dermatoses
by: Engin Yavuz, et al.
Published: (2010-06-01)

Reticulate dermatoses
by: Keshavmurthy A Adya, et al.
Published: (2014-01-01)

The dermatoses of pregnancy
by: Sachdeva Silonie
Published: (2008-01-01)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
by: Laura C Cappelli, et al.
Published: (2023-03-01)

Cross With Caution: Antibiotic Cross-Reactivity and Co-Reactivity Patterns in Severe Cutaneous Adverse Reactions
by: Grace Thompson, et al.
Published: (2021-02-01)

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
by: Susan C. Scott, et al.
Published: (2022-08-01)

Dermatose Glútea Senil
by: Joana Barbosa, et al.
Published: (2023-05-01)

Acitretin in pediatric dermatoses
by: Manjyot Gautam, et al.
Published: (2016-01-01)

DERMATOSES VULVARES INFLAMATÓRIAS
by: Ermelindo Tavares, et al.
Published: (2011-12-01)

“Interface” Dermatoses: Revisited
by: Sasi Kiran Attili
Published: (2019-01-01)

Update on parasitic dermatoses,
by: Alberto Eduardo Cox Cardoso, et al.
Published: (2020-03-01)

Neutrophilic Dermatoses Revisited
by: Aristóteles Rosmaninho, et al.
Published: (2014-11-01)